Anti-ACOX2 TripleA Polyclonal antibody in lung cancer research
September 2022 (Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA)
Altered expression of ACOX2 in non-small cell lung cancer.
Peroxisomes are organelles that play essential roles in many metabolic processes, innate immunity, signal transduction, aging, and cancer. One key family of enzymes in this process is the peroxisomal acyl-CoA oxidases (ACOX1, ACOX2, ACOX3).
Researchers from the Memorial Sloan Kettering Cancer Center, New York, USA, and the Trinity College Dublin, Ireland, have recently published a study in BMC Pulmonary Medicine describing how ACOX2 may have potential clinical utility in the diagnosis, prognosis and stratification of patients with non-small cell lung cancer.
Our anti-ACOX2 TripleA Polyclonal antibody (HPA038280) was used in immunohistochemistry.
Read whole article here.